Navigation Links
Emmaus Life Sciences Issues Statement in Response to Announcement by AFH Holding & Advisory
Date:1/25/2013

TORRANCE, Calif., Jan. 25, 2013 /PRNewswire/ -- Emmaus Life Sciences, Inc., a company dedicated to the discovery, development and commercialization of innovative and cost effective treatments and therapies for rare diseases, today issued the following statement in response to an announcement issued January 24, 2013 by AFH Holding & Advisory, LLC.:

AFH Holding & Advisory and its counsel have misrepresented the nature and effect of a recent ruling by the Los Angeles Superior Court. Far from "preventing [Emmaus] from pursuing a lawsuit it had filed" against AFH Holding & Advisory, the court's decision merely stayed the proceedings in California and held that the claims are contractually required to be brought in Delaware, where Emmaus is currently engaged in litigation against AFH Holding & Advisory and its principal Amir Heshmatpour . The court's narrow and technical ruling in no way addressed the merits of Emmaus's claims, which management believes are strongly supported by the evidence. Neither this nor any further attempt by AFH Holding & Advisory to litigate by press release will dissuade Emmaus from pursuing its claims in whatever forum is appropriate for their adjudication.

About Emmaus Life Sciences
Emmaus is dedicated to the discovery, development and commercialization of innovative and cost-effective treatments and therapies for rare diseases.  

For more information, please visit www.emmauslifesciences.com.

Contacts:

Media: 
Lori Teranishi for Emmaus Life Sciences, Inc. 
415-981-1964
lteranishi@iqprinc.com  

Investors: 
Matt Sheldon for Emmaus Life Sciences, Inc. 
310-279
'/>"/>

SOURCE Emmaus Life Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Emmaus CEO Yutaka Niihara, M.D., Issues Statement In Connection with Status of Companys Phase III FDA Sickle Cell Treatment Trials
2. Emmaus Medical Marks Progression of Phase 3 Sickle Cell Disease Clinical Trial During Sickle Cell Awareness Month
3. European Commission Grants Orphan Medicinal Product Designation for Emmaus Medicals Sickle Cell Treatment
4. Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
5. IntelliCell BioSciences Receives Notice of Allowance for its US Patent for "Ultrasonic Cavitation of Adipose Tissue to Produce Stromal Vascular Fraction Regenerative Cells"
6. BioDelivery Sciences Announces Completion of BNX Safety Study
7. Government Hospitals in Ecuador Continue to Invest in Integrity Life Sciences Technology
8. Cumberland Emerging Technologies Expands Life Sciences Center
9. Regado Biosciences, Inc. to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York, NY
10. Pressure BioSciences Announces Conversion of All Remaining Series E Convertible Preferred Stock by Ironridge BioPharma
11. BioDelivery Sciences Announces $40 Million Registered Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ... healthcare conferences during the third quarter, the 2014 Avondale ... Healthcare 2014 Conference.  Alexza,s corporate presentation will be webcast ... each event are below: , 2014 Avondale ... Boston , MA.  The format is ...
(Date:7/29/2014)... ROCKVILLE, Md. , July 29, 2014  Synthetic ... anti-infective biologic and drug candidates targeting specific pathogens that ... view of the unusual market activity in the Company,s ... Company in accordance with its usual practice. The Company ... unusual market activity. About Synthetic Biologics, Inc. ...
(Date:7/29/2014)... 2014 Numotion,s Board of Directors has announced that ... be the company,s new Chief Executive Officer. ... GE where he worked primarily for GE Healthcare Services, running ... $5 billion. His most recent position was as President and ... am thrilled to join Numotion," said Mike Swinford . ...
Breaking Medicine Technology:Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 2Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 3Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity 2Numotion Names Mike Swinford CEO 2
... , , ... Group (MRG), the global authority on medical technology market intelligence, ... enteral feeding devices will be a key driver of the ... MRG,s new US and European Markets for Enteral Feeding ...
... , FORT COLLINS, Colo., Dec. 14 ... 250 mg (chenodiol tablets). On October 22, 2009, ... an important therapy for patients suffering from gallstones in ... disease or advanced age. , Chenodal prescriptions have started ...
Cached Medicine Technology:Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 2Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 3Manchester Announces Availability of Chenodal(TM) 2
(Date:7/29/2014)... have discovered a chemical alteration in a single human ... larger studies, could give doctors a simple blood test ... , The discovery, described online in The American ... gene involved in the function of the brain,s response ... what might otherwise be an unremarkable reaction to the ...
(Date:7/29/2014)... Denver, Colorado (PRWEB) July 29, 2014 Daily ... the author of this program claims that he cured his ... the author decided to share part of his experience. ... nasal polys permanently and naturally in just 4 days. Since ... share it with sufferers from all around the world. ...
(Date:7/29/2014)... Daily Gossip reveals in its Leaky Gut Cure ... and functional medicine practitioner, who spent years looking for a ... suffered from leaky gut, too, so this is what determined ... treatment. , Karen Brimeyer decided to share her story, ... the world. The author of the Leaky Gut Cure program ...
(Date:7/29/2014)... New York (PRWEB) July 29, 2014 ... protecting the rights of victims injured by defective drugs ... has been filed by plaintiffs in Canada who allege ... of cardiovascular events with the low testosterone injection ... on July 22, 2014 in the Ontario Superior Court ...
(Date:7/29/2014)... 29, 2014 Daily Gossip reveals in its ... holistic system that will permanently eliminate all the symptoms associated ... natural treatment will banish symptoms such as mild hearing loss, ... heard by patients will be gone forever. , The method ... The author of this program says that at the end ...
Breaking Medicine News(10 mins):Health News:A blood test for suicide? 2Health News:A blood test for suicide? 3Health News:Nasal Polyps Treatment Miracle Review Reveals How to Cure Nasal Polyps Without Surgery 2Health News:Leaky Gut Cure Review Reveals Karen Brimeyer’s Natural Way to Heal Leaky Gut 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 3Health News:Tinnitus Miracle Review Exposes the Only Holistic System for Tinnitus Cure 2
... , ARLINGTON, Va., July 23 During ... Majority Leader Tom Daschle and Blue Dog Democrat Rep. Jason ... in the reform of the U.S. healthcare system. The ... medical equipment and services. The American Association for Homecare hosted ...
... , , , ... ), a leading provider of optical components, modules and subsystems, today announced ... June 27, 2009. Oclaro, Inc. was formed April 27, 2009 from ... Avanex Corporation. , , "Being positive Adjusted ...
... Calif., July 23 Oscar Wright, chief executive officer of United Advocates ... Donuts shop, participated in an interview and debate Wednesday on KTVU,s ... , Oscar Wright released this statement today: , ... the U.S. Small Business Administration, I appreciate an individual,s goal to live ...
... might be slowing down among poor families , THURSDAY, ... low-income families in the United States are considered obese, a ... that the news is not all bad: The childhood obesity ... this group. , Among 2- to 4-year-olds from low-income families, ...
... , , PITTSBURGH, July 23 ... stopping in Pennsylvania throughout the week of July 27-31 at ... access information on programs that provide prescription medicines for free ... 8.2 percent -- compared to 5.1% a year ago -- ...
... a cancer-killing protein, scientists at the University of Kentucky,s Markey ... UK professor of radiation medicine, have determined that the tumor-suppressor ... expressing the Par-4 gene, is in fact secreted by most ... cancer cells by binding to receptors on the cell surface. ...
Cached Medicine News:Health News:Sen. Tom Daschle, Rep. Jason Altmire, Healthcare Experts Tout Homecare as Cost-Effective Solution in the Healthcare Reform Process 2Health News:Sen. Tom Daschle, Rep. Jason Altmire, Healthcare Experts Tout Homecare as Cost-Effective Solution in the Healthcare Reform Process 3Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 2Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 3Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 4Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 5Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 6Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 7Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 8Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 9Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 10Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 11Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 12Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 13Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 14Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 15Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 16Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 17Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 18Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 19Health News:Mental Health Advocates Call for Psycho Donuts to Do the Right Thing 2Health News:1 in 7 Low-Income Preschoolers Is Obese 2Health News:Partnership for Prescription Assistance Prepared to Help Pennsylvania Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Pennsylvania Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared to Help Pennsylvania Workers Hurt by Recession 4Health News:Human cells secrete cancer-killing protein, UK study finds 2
... there is a more efficient way ... fully portable battery operated patient warming ... surgical teams with a compact and ... the entire surgical process. Its unique ...
... patient warming system consists of our ... range of blankets for use with ... clinical applications. Blankets are available for ... and paediatric sizes and a sterile ...
MAMMOMAT 3000 Nova supports high-volume screening as well as interventional diagnostics. Versatile procedural capabilities include magnification, stereotactic biopsy, needle localization, and specime...
The Synoptiscope(L-2510B) has a wide variety of functions including binocular function diagnosis and treatment....
Medicine Products: